<p>, /PRNewswire/ --</p>
<p>原因：罗森律师事务所是一家全球投资者权益律师事务所，宣布代表在 2025 年 3 月 24 日至 2026 年 3 月 12 日（包括该日期）期间购买 Immutep Ltd.（纳斯达克代码：IMMP）美国存托凭证（&#34;ADRs&#34;）的投资者提起集体诉讼（&#34;集体诉讼期间&#34;）。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 7 月 6 日之前向法院提出申请。</p>
<p>那么：如果您在集体诉讼期间购买了 Immutep 的 ADRs，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
<p>接下来该做什么：要加入 Immutep 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=56430 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 7 月 6 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的事务所没有可比的经验、资源或任何有意义的同行认可。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者获得了超过 4.38 亿美元的赔偿。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已被 Lawdragon 和 Super Lawyers 认可。</p>
<p>案件详情：根据诉讼，整个集体诉讼期间，被告做出了虚假和/或误导性的陈述，并/或隐瞒了 TACTI004 试验的状态和前景，基于 eftilagimod alfa（&#34;efti&#34;）在其他试验中的持续积极疗效和安全性结果，特别是在 Immutep 之前的 TACTI-002 和 INSIGHT-003 研究的积极顶线结果之后。此外，被告在 2026 年 1 月 30 日向证券交易委员会提交的 K 表中宣布，该试验显示出 “强劲的运营进展”，并且计划中的中期无效性分析仍 “按计划进行，预计在 2026 年第一季度完成”。实际上，Immutep 意识到或由于其对内部临床数据、分析和关于 TACTI-004 试验及其计划中期无效性评估的报告的访问而表现出鲁莽，现有信息大大增加了该研究未能达到其主要疗效和/或安全性终点的风险。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 Immutep 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=56430 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证之前，除非您聘请律师，否则您不受律师的代表。您可以选择自己喜欢的律师。您也可以保持缺席集体成员的身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
<p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/.</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所，P.A.</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约，NY 10016</p>
<p>电话：(212) 686-1060</p>
<p>免费电话：(866) 767-3653</p>
<p>传真：(212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所，P.A.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REM2MzY2OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxOTU1UFJfTkVXU19VU1BSX19fX19EQzYzNjY5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REM2MzY2OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxOTU1UFJfTkVXU19VU1BSX19fX19EQzYzNjY5"/></p>

IMMP

<p>罗森律师事务所已宣布对 2025 年 3 月 24 日至 2026 年 3 月 12 日期间购买 Immutep Ltd. ADR 的投资者提起集体诉讼。投资者可能有权在没有前期费用的情况下获得赔偿。诉讼声称 Immutep 误导投资者关于 TACTI-004 试验的状态，导致真相浮出水面时造成损失。感兴趣的方必须在 2026 年 7 月 6 日前申请担任首席原告</p>

<p>, /PRNewswire/ --</p>
<div class="lb-trans"><p>, /PRNewswire/ --</p>
</div><p>Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Receipts (&#34;ADRs&#34;) of Immutep Ltd. (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026, inclusive (the &#34;Class Period&#34;). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026.</p>
<div class="lb-trans"><p>原因：罗森律师事务所是一家全球投资者权益律师事务所，宣布代表在 2025 年 3 月 24 日至 2026 年 3 月 12 日（包括该日期）期间购买 Immutep Ltd.（纳斯达克代码：IMMP）美国存托凭证（&#34;ADRs&#34;）的投资者提起集体诉讼（&#34;集体诉讼期间&#34;）。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 7 月 6 日之前向法院提出申请。</p>
</div><p>So what: If you purchased Immutep ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么：如果您在集体诉讼期间购买了 Immutep 的 ADRs，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the Immutep class action, go to https://rosenlegal.com/submit-form/?case_id=56430 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 Immutep 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=56430 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 7 月 6 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的事务所没有可比的经验、资源或任何有意义的同行认可。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年都排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者获得了超过 4.38 亿美元的赔偿。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已被 Lawdragon 和 Super Lawyers 认可。</p>
</div><p>Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed the status and prospects of the TACTI004 trial based on continuing positive efficacy and safety readouts of eftilagimod alfa's (&#34;efti&#34;) performance in other trials, particularly following positive top-line results from Immutep's prior TACTI-002 and INSIGHT-003 studies. Further, defendants announced in a Form-K filed with the Securities and Exchange Commission in January 30, 2026, that the trial was exhibiting &#34;strong operational progress&#34; and the planned interim futility analysis remained &#34;on track for the first quarter of 2026.&#34; In truth, Immutep were aware of or were reckless, based on their access to internal clinical data, analyses, and reports concerning the TACTI-004 trial and its planned interim futility evaluation, that then-existing information materially increased the risk that the study would fail to meet its primary efficacy and/or safety endpoints. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据诉讼，整个集体诉讼期间，被告做出了虚假和/或误导性的陈述，并/或隐瞒了 TACTI004 试验的状态和前景，基于 eftilagimod alfa（&#34;efti&#34;）在其他试验中的持续积极疗效和安全性结果，特别是在 Immutep 之前的 TACTI-002 和 INSIGHT-003 研究的积极顶线结果之后。此外，被告在 2026 年 1 月 30 日向证券交易委员会提交的 K 表中宣布，该试验显示出 “强劲的运营进展”，并且计划中的中期无效性分析仍 “按计划进行，预计在 2026 年第一季度完成”。实际上，Immutep 意识到或由于其对内部临床数据、分析和关于 TACTI-004 试验及其计划中期无效性评估的报告的访问而表现出鲁莽，现有信息大大增加了该研究未能达到其主要疗效和/或安全性终点的风险。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the Immutep class action, go to https://rosenlegal.com/submit-form/?case_id=56430 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Immutep 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=56430 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证之前，除非您聘请律师，否则您不受律师的代表。您可以选择自己喜欢的律师。您也可以保持缺席集体成员的身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/.</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所，P.A.</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约，NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话：(212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话：(866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真：(212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所，P.A.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REM2MzY2OSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxOTU1UFJfTkVXU19VU1BSX19fX19EQzYzNjY5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC63669&amp;Transmission_Id=202605191955PR_NEWS_USPR_____DC63669&amp;DateId=20260519"/></p>

IMMP 的投资者有机会主导针对 Immutep Ltd.的证券欺诈诉讼